Pre- and Postexposure Use of Human Monoclonal Antibody against H5N1 and H1N1 Influenza Virus in Mice: Viable Alternative to OseltamivirKOUDSTAAL, Wouter; KOLDIJK, Martin H; BRAKENHOFF, Just P. J et al.The Journal of infectious diseases. 2009, Vol 200, Num 12, pp 1870-1873, issn 0022-1899, 4 p.Article

Neutralizing antibodies and CD8⁺ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectorsSUMIDA, Shawn M; TRUITT, Diana M; HAVENGA, Menzo J. E et al.Journal of virology. 2004, Vol 78, Num 6, pp 2666-2673, issn 0022-538X, 8 p.Article

A Highly Conserved Neutralizing Epitope on Group 2 Influenza A VirusesEKIERT, Damian C; FRIESEN, Robert H. E; VOGELS, Ronald et al.Science (Washington, D.C.). 2011, Vol 333, Num 6044, pp 843-850, issn 0036-8075, 8 p.Article

Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccineSAMINA, Itzchak; HAVENGA, Menzo; UYTDEHAAG, Fons et al.Vaccine. 2007, Vol 25, Num 49, pp 8338-8345, issn 0264-410X, 8 p.Article

Highly Conserved Protective Epitopes on Influenza B VirusesDREYFUS, Cyrille; LAURSEN, Nick S; DER VLUGT, Remko Van et al.Science (Washington, D.C.). 2012, Vol 337, Num 6100, pp 1343-1348, issn 0036-8075, 6 p.Article

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vectorKOSTENSE, Stefan; KOUDSTAAL, Wouter; GOUDSMIT, Jaap et al.AIDS (London). 2004, Vol 18, Num 8, pp 1213-1216, issn 0269-9370, 4 p.Article

Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: Addressing preexisting immunity to vaccine and gene therapy vectorsSPRANGERS, Mieke C; LAKHAI, Wandena; KOUDSTAAL, Wouter et al.Journal of clinical microbiology (Print). 2003, Vol 41, Num 11, pp 5046-5052, issn 0095-1137, 7 p.Article